223 related articles for article (PubMed ID: 29194289)
1. Lack of Detection of New Amphetamine-Like Drugs Using Conventional Urinary Immunoassays.
Begeman A; Franssen EJF
Ther Drug Monit; 2018 Feb; 40(1):135-139. PubMed ID: 29194289
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the sensitivity and specificity of six immunoassays for the detection of amphetamines in urine.
Verstraete AG; Heyden FV
J Anal Toxicol; 2005; 29(5):359-64. PubMed ID: 16105261
[TBL] [Abstract][Full Text] [Related]
3. Cross-reactivity studies and predictive modeling of "Bath Salts" and other amphetamine-type stimulants with amphetamine screening immunoassays.
Petrie M; Lynch KL; Ekins S; Chang JS; Goetz RJ; Wu AH; Krasowski MD
Clin Toxicol (Phila); 2013 Feb; 51(2):83-91. PubMed ID: 23387345
[TBL] [Abstract][Full Text] [Related]
4. Performance characteristics of selected immunoassays for preliminary test of 3,4-methylenedioxymethamphetamine, methamphetamine, and related drugs in urine specimens.
Hsu J; Liu C; Liu CP; Tsay WI; Li JH; Lin DL; Liu RH
J Anal Toxicol; 2003 Oct; 27(7):471-8. PubMed ID: 14607002
[TBL] [Abstract][Full Text] [Related]
5. Reduced interference by phenothiazines in amphetamine drug of abuse immunoassays.
Melanson SE; Lee-Lewandrowski E; Griggs DA; Long WH; Flood JG
Arch Pathol Lab Med; 2006 Dec; 130(12):1834-8. PubMed ID: 17149959
[TBL] [Abstract][Full Text] [Related]
6. False positive amphetamines and 3,4-methylenedioxymethamphetamine immunoassays in the presence of metoprolol-two cases reported in clinical toxicology.
Leclercq M; Soichot M; Delhotal-Landes B; Bourgogne E; Gourlain H; Mégarbane B; Labat L
J Anal Toxicol; 2020 Mar; 44(2):200-205. PubMed ID: 31384953
[TBL] [Abstract][Full Text] [Related]
7. Comparison of three commercial amphetamine immunoassays for detection of methamphetamine, methylenedioxyamphetamine, methylenedioxymethamphetamine, and methylenedioxyethylamphetamine.
Ruangyuttikarn W; Moody DE
J Anal Toxicol; 1988; 12(4):229-33. PubMed ID: 2903272
[TBL] [Abstract][Full Text] [Related]
8. Determination of designer drug cross-reactivity on five commercial immunoassay screening kits.
Regester LE; Chmiel JD; Holler JM; Vorce SP; Levine B; Bosy TZ
J Anal Toxicol; 2015 Mar; 39(2):144-51. PubMed ID: 25492523
[TBL] [Abstract][Full Text] [Related]
9. Comparison of several immunoassays used in drugs of abuse screening: Assessment against gold standard methods and calculation of measurement uncertainty.
Mina A
J Pharmacol Toxicol Methods; 2020; 101():106649. PubMed ID: 31730939
[TBL] [Abstract][Full Text] [Related]
10. Detectability of new psychoactive substances, 'legal highs', in CEDIA, EMIT, and KIMS immunochemical screening assays for drugs of abuse.
Beck O; Rausberg L; Al-Saffar Y; Villen T; Karlsson L; Hansson T; Helander A
Drug Test Anal; 2014 May; 6(5):492-9. PubMed ID: 24665024
[TBL] [Abstract][Full Text] [Related]
11. Performance of immunoassays in screening for opiates, cannabinoids and amphetamines in post-mortem blood.
Hino Y; Ojanperä I; Rasanen I; Vuori E
Forensic Sci Int; 2003 Jan; 131(2-3):148-55. PubMed ID: 12590054
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the triage system for emergency drugs-of-abuse testing in urine.
Wu AH; Wong SS; Johnson KG; Callies J; Shu DX; Dunn WE; Wong SH
J Anal Toxicol; 1993; 17(4):241-5. PubMed ID: 8371556
[TBL] [Abstract][Full Text] [Related]
13. Cross-reactivities of various phenethylamine-type designer drugs to immunoassays for amphetamines, with special attention to the evaluation of the one-step urine drug test Instant-View™, and the Emit® assays for use in drug enforcement.
Nakanishi K; Miki A; Zaitsu K; Kamata H; Shima N; Kamata T; Katagi M; Tatsuno M; Tsuchihashi H; Suzuki K
Forensic Sci Int; 2012 Apr; 217(1-3):174-81. PubMed ID: 22154438
[TBL] [Abstract][Full Text] [Related]
14. Differentiation of amphetamine/methamphetamine and other cross-immunoreactive sympathomimetic amines in urine samples by serial dilution testing.
Woodworth A; Saunders AN; Koenig JW; Moyer TP; Turk J; Dietzen DJ
Clin Chem; 2006 Apr; 52(4):743-6. PubMed ID: 16455869
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of ephedrine, pseudoephedrine and phenylpropanolamine concentrations in human urine samples and a comparison of the specificity of DRI amphetamines and Abuscreen online (KIMS) amphetamines screening immunoassays.
Stout PR; Klette KL; Horn CK
J Forensic Sci; 2004 Jan; 49(1):160-4. PubMed ID: 14979364
[TBL] [Abstract][Full Text] [Related]
16. Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine.
Krasowski MD; Pizon AF; Siam MG; Giannoutsos S; Iyer M; Ekins S
BMC Emerg Med; 2009 Apr; 9():5. PubMed ID: 19400959
[TBL] [Abstract][Full Text] [Related]
17. [The urinary screening and identification of amphetamines in clinical toxicology laboratory--VGH].
Lin WL; Deng JF; Chou LJ; Hung DZ; Tsai WJ
Zhonghua Yi Xue Za Zhi (Taipei); 1991 Oct; 48(4):305-9. PubMed ID: 1659927
[TBL] [Abstract][Full Text] [Related]
18. Profiles of urine samples taken from Ecstasy users at Rave parties: analysis by immunoassays, HPLC, and GC-MS.
Zhao H; Brenneisen R; Scholer A; McNally AJ; ElSohly MA; Murphy TP; Salamone SJ
J Anal Toxicol; 2001; 25(4):258-69. PubMed ID: 11386639
[TBL] [Abstract][Full Text] [Related]
19. False-Positive Amphetamines in Urine Drug Screens: A 6-Year Review.
Pope JD; Drummer OH; Schneider HG
J Anal Toxicol; 2023 Mar; 47(3):263-270. PubMed ID: 36367744
[TBL] [Abstract][Full Text] [Related]
20. Signify ER Drug Screen Test evaluation: comparison to Triage Drug of Abuse Panel plus tricyclic antidepressants.
Phillips JE; Bogema S; Fu P; Furmaga W; Wu AH; Zic V; Hammett-Stabler C
Clin Chim Acta; 2003 Feb; 328(1-2):31-8. PubMed ID: 12559596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
